Literature DB >> 10069285

Heparin management test versus activated coagulation time during cardiovascular surgery: correlation with anti-Xa activity.

J C Fitch1, K L Geary, G P Mirto, D W Byrne, R L Hines.   

Abstract

OBJECTIVE: To compare the abilities of the heparin management test (HMT) and the activated coagulation time (ACT) to provide a measurement of heparin effect in patients undergoing cardiac or peripheral vascular surgery. These measurements of heparin effect were also compared with measurements of heparin concentrations tested by anti-Xa activity. A secondary objective was to compare the performance of the noncitrated HMT with that of the citrated HMT.
DESIGN: A prospective study.
SETTING: A single-center study conducted in a university hospital. PARTICIPANTS: After human investigation committee approval and informed consent were obtained, adult patients undergoing cardiac or peripheral vascular surgery were included in this study.
INTERVENTIONS: In both surgical groups, blood was sampled for ACT, HMT, and anti-Xa activity. Each HMT was performed on both noncitrated and citrated samples.
MEASUREMENTS AND MAIN RESULTS: As an indicator of heparin effect, the HMT had a strong correlation with the ACT (r = 0.899; p < 0.01). In addition, the HMT had a significantly stronger correlation with anti-Xa activity than the ACT (p < 0.01). The correlation obtained from the noncitrated samples was identical with that obtained from the citrated samples (r = 0.819; p < 0.001 for both groups).
CONCLUSION: The ability of the HMT and the ACT to measure heparin effect was similar. The HMT performed better than the ACT when using anti-Xa activity as a measure of heparin concentration. Noncitrated HMT results were similar to citrated HMT results, thus supporting the use of fresh whole blood for testing purposes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10069285     DOI: 10.1016/s1053-0770(99)90174-x

Source DB:  PubMed          Journal:  J Cardiothorac Vasc Anesth        ISSN: 1053-0770            Impact factor:   2.628


  3 in total

1.  Relationship between the heparin management test and the HemoTec activated clotting time in patients undergoing percutaneous coronary intervention.

Authors:  S Tsimikas; R Beyer; A Hassankhani
Journal:  J Thromb Thrombolysis       Date:  2001-05       Impact factor: 2.300

Review 2.  The hemostatic defect of cardiopulmonary bypass.

Authors:  Matthew Dean Linden
Journal:  J Thromb Thrombolysis       Date:  2003-12       Impact factor: 2.300

3.  Point-of-Care Testing of Hemostasis in Cardiac Surgery.

Authors:  Domenico Prisco; Rita Paniccia
Journal:  Thromb J       Date:  2003-05-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.